1.
N Engl J Med
; 391(8): 773, 2024 Aug 22.
Article
in English
| MEDLINE
| ID: mdl-39167817
Subject(s)
Anticoagulation Reversal , Cerebral Hemorrhage , Factor Xa Inhibitors , Factor Xa , Recombinant Proteins , Humans , Anticoagulation Reversal/adverse effects , Anticoagulation Reversal/methods , Cerebral Hemorrhage/chemically induced , Cerebral Hemorrhage/drug therapy , Clinical Trials, Phase IV as Topic , Factor Xa/administration & dosage , Factor Xa/adverse effects , Factor Xa Inhibitors/adverse effects , Multicenter Studies as Topic , Randomized Controlled Trials as Topic , Recombinant Proteins/administration & dosage , Recombinant Proteins/adverse effects , Research Design , Rivaroxaban/adverse effects
2.
N Engl J Med
; 391(8): 773-774, 2024 Aug 22.
Article
in English
| MEDLINE
| ID: mdl-39167818
Subject(s)
Anticoagulation Reversal , Cerebral Hemorrhage , Factor Xa Inhibitors , Factor Xa , Recombinant Proteins , Humans , Cerebral Hemorrhage/chemically induced , Cerebral Hemorrhage/drug therapy , Factor Xa/administration & dosage , Factor Xa/adverse effects , Factor Xa Inhibitors/adverse effects , Recombinant Proteins/administration & dosage , Recombinant Proteins/adverse effects , Rivaroxaban/adverse effects , Multicenter Studies as Topic , Anticoagulation Reversal/adverse effects , Anticoagulation Reversal/methods , Clinical Trials, Phase IV as Topic , Research Design , Randomized Controlled Trials as Topic
3.
N Engl J Med
; 391(8)2024 Aug 22.
Article
in English
| MEDLINE
| ID: mdl-39167819
Subject(s)
Anticoagulation Reversal , Cerebral Hemorrhage , Factor Xa Inhibitors , Factor Xa , Recombinant Proteins , Humans , Anticoagulation Reversal/adverse effects , Anticoagulation Reversal/methods , Cerebral Hemorrhage/chemically induced , Cerebral Hemorrhage/drug therapy , Clinical Trials, Phase IV as Topic , Factor Xa/administration & dosage , Factor Xa/adverse effects , Factor Xa Inhibitors/adverse effects , Multicenter Studies as Topic , Randomized Controlled Trials as Topic , Recombinant Proteins/administration & dosage , Recombinant Proteins/adverse effects , Research Design , Rivaroxaban/adverse effects
4.
N Engl J Med
; 391(8): 772-773, 2024 Aug 22.
Article
in English
| MEDLINE
| ID: mdl-39167816